Davidson Investment Advisors Has $18.32 Million Stock Position in Bristol Myers Squibb Company (NYSE:BMY)

Davidson Investment Advisors lifted its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 3.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 300,366 shares of the biopharmaceutical company's stock after purchasing an additional 9,045 shares during the quarter. Davidson Investment Advisors' holdings in Bristol Myers Squibb were worth $18,319,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Polar Asset Management Partners Inc. bought a new stake in shares of Bristol Myers Squibb in the 4th quarter worth about $16,651,000. Avaii Wealth Management LLC grew its holdings in Bristol Myers Squibb by 590.9% during the 1st quarter. Avaii Wealth Management LLC now owns 78,597 shares of the biopharmaceutical company's stock worth $4,794,000 after acquiring an additional 67,221 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in Bristol Myers Squibb by 1.4% during the 1st quarter. Assenagon Asset Management S.A. now owns 65,038 shares of the biopharmaceutical company's stock worth $3,967,000 after acquiring an additional 869 shares during the last quarter. Shorepoint Capital Partners LLC grew its holdings in Bristol Myers Squibb by 2.2% during the 4th quarter. Shorepoint Capital Partners LLC now owns 58,426 shares of the biopharmaceutical company's stock worth $3,305,000 after acquiring an additional 1,248 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in Bristol Myers Squibb by 17.0% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 550,613 shares of the biopharmaceutical company's stock worth $33,582,000 after acquiring an additional 80,087 shares during the last quarter. Institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Trading Down 0.9%

Bristol Myers Squibb stock traded down $0.42 during midday trading on Monday, hitting $46.50. 10,683,820 shares of the stock were exchanged, compared to its average volume of 12,874,009. The company has a fifty day simple moving average of $47.73 and a two-hundred day simple moving average of $53.58. Bristol Myers Squibb Company has a 52 week low of $39.50 and a 52 week high of $63.33. The stock has a market capitalization of $94.63 billion, a PE ratio of 17.42, a P/E/G ratio of 1.39 and a beta of 0.36. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The business had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same quarter last year, the firm earned ($4.40) EPS. Bristol Myers Squibb's quarterly revenue was down 5.6% compared to the same quarter last year. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be issued a dividend of $0.62 per share. The ex-dividend date is Thursday, July 3rd. This represents a $2.48 annualized dividend and a yield of 5.33%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 92.88%.

Wall Street Analyst Weigh In

BMY has been the topic of a number of research analyst reports. UBS Group decreased their price objective on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Argus raised shares of Bristol Myers Squibb to a "hold" rating in a report on Friday, April 25th. Wall Street Zen lowered shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Piper Sandler initiated coverage on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective on the stock. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $55.00 price objective on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $58.00.

Insider Buying and Selling

In related news, EVP Samit Hirawat bought 4,250 shares of the company's stock in a transaction on Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the acquisition, the executive vice president owned 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This represents a 5.36% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.07% of the company's stock.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.